Garth Lees-Rolfe
CFO
CFO
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Inhibikase Therapeutics, Inc. (IKT) | Former Chief Financial Officer | $306,990 | $1,210,184 |
Executive changes
-
Resigned Chief Financial Officer, principal financial officer and principal accounting officer at Inhibikase Therapeutics, Inc. (IKT)2025-04-11
Earnings-call appearances
-
Inhibikase Therapeutics, Inc. Q2 FY2024 Earnings Call2024-06-30
Inhibikase Therapeutics, Inc. (IKT)
-
Inhibikase Therapeutics, Inc. Q1 FY2024 Earnings Call2024-03-31
Inhibikase Therapeutics, Inc. (IKT)
-
Inhibikase Therapeutics, Inc. Q4 FY2023 Earnings Call2023-12-31
Inhibikase Therapeutics, Inc. (IKT)